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Abstract
Motivation
Using molecular similarity to discover bioactive small molecules with novel chemical scaf-
folds can be computationally demanding. We describe Ultra-fast Shape Recognition with
Atom Types (UFSRAT), an efficient algorithm that considers both the 3D distribution
(shape) and electrostatics of atoms to score and retrieve molecules capable of making
similar interactions to those of the supplied query.
Results
Computational optimization and pre-calculation of molecular descriptors enables a query
molecule to be run against a database containing 3.8 million molecules and results returned
in under 10 seconds on modest hardware. UFSRAT has been used in pipelines to identify
bioactive molecules for two clinically relevant drug targets; FK506-Binding Protein 12 and
11β-hydroxysteroid dehydrogenase type 1. In the case of FK506-Binding Protein 12,
UFSRAT was used as the first step in a structure-based virtual screening pipeline, yielding
many actives, of which the most active shows a KD, app of 281 µM and contains a substruc-
ture present in the query compound. Success was also achieved running solely the
UFSRAT technique to identify new actives for 11β-hydroxysteroid dehydrogenase type 1,
for which the most active displays an IC50 of 67 nM in a cell based assay and contains a
substructure radically different to the query. This demonstrates the valuable ability of the
UFSRAT algorithm to perform scaffold hops.
Availability and Implementation
A web-based implementation of the algorithm is freely available at http://opus.bch.ed.ac.uk/
ufsrat/.
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Introduction
The concept of molecular similarity has been exploited in nearly all chemical fields and has been
used to great effect in the pharmaceutical industry to reduce the massive cost of drug develop-
ment [1–3]. When molecular similarity is employed in ligand-based virtual screening it offers
the ability to carry out searches for actives where little is known about the drug receptor, only
molecules which bind to it [4–8]. Structurally similar molecules can exhibit similar biological
properties and may therefore bind to receptors, making the same or equivalent interactions as
the native ligand [6, 9]. Molecular similarity and more specifically, scaffold hopping also pro-
vides a route to ‘rescue’ problematic drug leads which may well be inhibitors of a protein, but are
unsuitable for further development due to problems with pharmacology, pharmacokinetics or
patent issues [3, 10]. Scaffold hopping describes the discovery of a compound with the same or
similar bioactivity as the query compound but with a different core molecular structure. Success-
ful scaffold hopping methodologies commonly describe the virtual compound in a way that en-
codes both the 3D shape of the molecule and the electrostatic and hydrophobic properties. This
is key to successful lead discovery because electrostatic and van der Waals interactions are very
sensitive to bond geometry and distance. There is of course a direct correlation between the lev-
els of detail encoded in molecular descriptors or force-field based approaches and computational
resources. It is essential to develop algorithms that can succinctly capture the essential molecular
features and then search very large databases in a computationally efficient manner. We have de-
veloped the idea of capturing molecular shape using parameters determined from the interatom-
ic distance distributions first proposed by Ballester and Richards [11, 12] and incorporate these
pre-calculated molecular descriptors into a searchable database of available compounds [13].
In this paper we describe the use of our UFSRAT algorithm (an expansion of the validated
[14–19] USR technique) in virtual screening pipelines to identify inhibitors of two unrelated
enzymes; FK506-Binding Protein 12 (FKBP12) and 11β-hydroxysteroid dehydrogenase type 1
(11β-HSD1). FKBP12 is a peptidyl-prolyl isomerase, catalysing protein folding [20–22] and is
a therapeutic target for Parkinson’s and Alzheimer’s disease [23]. The enzyme 11β-HSD1 catal-
yses the intracellular biosynthesis of the active glucocorticoid steroid hormone cortisol which
plays a central role in glucose homeostasis and the inflammatory response [24, 25]. Inhibitors
of 11β-HSD1 have been investigated for targeting cardiometabolic diseases such as type-2 dia-
betes, as well as glaucoma, osteoporosis and Alzheimer’s disease. Cellular and direct binding as-
says show that UFSRAT successfully identified highly active non-steroid inhibitors with
nanomolar activity.
Methods
Computational Methods: Ultra fast shape recognition with atom types
Applying the Ultra Fast Shape Recognition with Atom Types (UFSRAT) technique to a query
molecule and a candidate molecule returns a measure of similarity between the two. This pro-
cess consists of three steps: first shape and atom property descriptors are calculated for each
molecule; second, the descriptors are compared using a scoring function and finally similar
molecules are ranked by score. Ballester and Richards outlined Ultrafast Shape Recognition
(USR) [11, 12] an algorithm that can be used to assess the shape similarity between two mole-
cules. With this approach, no distinction is made between different types of atom. UFSRAT
has been developed using USR as the base concept but additionally encodes hydrophobic and
electrostatic information; features of the molecule that are important in molecular recognition.
Calculating descriptors. UFSRAT calculates 4 descriptor sets for each virtual molecule;
each set encodes different features of the molecule. The distributions used to generate UFSRAT
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descriptors are: All atoms (shape), hydrophobic atoms, hydrogen bond acceptor atoms and hy-
drogen bond donor atoms.
Determining which atoms within a molecule should be considered for each distribution re-
quires atom type information to be calculated. Atom typing can be described as applying a user
definable atomic mask. This is achieved using the same implementation present in the high
throughput virtual screening code LIDAEUS [26, 27]. Fig. 1 illustrates the generation of
UFSRAT distributions whilst Fig. 2 shows how the descriptors are calculated. 12 descriptors
are calculated for each of the 4 distributions resulting in 48 descriptors for each molecule. This
is an additional 36 compared to USR which only uses an all atom distribution. The 12 descrip-
tors for each set are calculated from the geometric atom distributions. Fig. 2 illustrates a simpli-
fied all atom distribution descriptor generation process applied to a 2D small molecule (note
that hydrogens are ignored). Calculating the 12 values takes the following form; (i) Atomic
coordinates are used to define the centre of the volume occupied by the molecule as point 1
(P1). (ii) A distribution of Euclidean distances of all atoms to P1 is generated. (iii) From this
Figure 1. The four UFSRAT distributions from typed atoms. Amolecule is broken down into four distributions, consisting of all atoms, hydrophobic,
hydrogen bond acceptor and hydrogen bond donor.
doi:10.1371/journal.pone.0116570.g001
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distribution, 3 values are determined; the mean, variance and skew. These three values for all
atoms relative to P1 make up the first 3 of the 12 descriptors. (iv) The closest atom to the geo-
metric centre is defined as point 2 (P2). Similarly, the Euclidian distances of all atoms to P2 are
calculated and the mean, variance and skew of this distribution are determined. These make up
descriptor values 4, 5 and 6. (v) The furthest atom from P2 is defined as point 3 (P3). Again,
the mean, variance and skew of the distribution made up of Euclidian distances of all atoms to
P3 go to make up values 7, 8 and 9 of the descriptors. (vi) Finally, point 4 (P4) is the furthest
atom from P3. To make up the final three values of the twelve descriptors, the Euclidian dis-
tance of all atoms from this point are calculated and then the mean, variance and skew calculat-
ed from this distribution.
Figure 2. Generation of UFSRAT all atom descriptors for the P1 distribution. The atoms in a molecule
are all considered as an array of points (black open circles). P1 represents the geometric centre of the atoms
(black dot). Euclidean distances are calculated to all atoms from P1 (grey lines). The 3 descriptors for the P1
distribution are the mean, variance and skew of the distance distribution.
doi:10.1371/journal.pone.0116570.g002
UFSRAT Aided Discovery of FKBP12 and 11βHSD1 Inhibitors
PLOS ONE | DOI:10.1371/journal.pone.0116570 February 6, 2015 4 / 15
Comparing molecular descriptors. The 48 geometric distribution descriptors are pre-cal-
culated for each candidate molecule in the database and stored as vectors Mc. Mq represents
the vector for the query molecule. The USFRAT scoring function is used to generate a similari-
ty score, Sqc, between the query molecule and each candidate molecule in the database. This is
illustrated in Fig. 3. The similarity score Sqc is a single numerical metric pertaining to the pre-
dicted similarity of the molecules. As candidate molecules are tested against the query, a sorted
list of the top matches is kept and returned as the result upon completion.
Ranking compounds by similarity. The similarity scoring function Sqc is an extension of
the method used by USR, calculating a weighted difference for each distribution and scaling
the result between 0 and 1. UFSRAT is therefore typically used to screen a large database of
potential candidate molecules against a query resulting in a ranked list of arbitrary length such
as the top 500 similars.
UFSRAT—execution. A high speed version UFSRAT is currently deployed on the Univer-
sity of Edinburgh’s EDULISS system [13]. EDULISS is a web based molecular database mining
tool. Containing 3.8 million unique compounds, the system employs a number of methods for
similarity searching. The inclusion of UFSRAT into this system as a similarity method has en-
abled the pre calculation of UFSRAT descriptors for each of the 3.8 million molecules. Storage
of pre-calculated descriptors is achieved using one binary data file. Storing all required infor-
mation along with a unique identifier for a molecule requires 200 bytes. This is made up of 8
bytes for the identifier, and 192 bytes for the 48 descriptor values. UFSRAT therefore requires
730 megabytes of data to represent 3.8 million compounds in a condensed form suitable for
similarity searching. Pre-calculating the descriptors in this way enables UFSRAT to read in the
query molecule supplied by the user and then only ever calculate descriptors for the query.
The scoring is then performed on the pre-calculated descriptors along with the newly generated
Figure 3. The UFSRAT Scoring function.UFSRAT descriptor values have been calculated for the molecules shown and their values input to the scoring
function shown. Sqc is the similarity score between the two molecules q and c (query and candidate), M being a vector representing the 48 geometric
distribution descriptors.
doi:10.1371/journal.pone.0116570.g003
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query molecule descriptors. Upon completion, unique identifiers are used to retrieve top scor-
ing molecules from the database and return them to the user in the form of a multi-molecule
MDL-SD file. This approach results in a run time of around 8 seconds to query a molecule
against the whole database of candidate molecules and supply results to the user using a modest
2010 linux-based server running on 1 processor. Linear multiprocessor speedup has also been
achieved by removing disk operations from timings and parallelization using the OpenMP
shared memory paradigm [28] on up to 8 processors.
The FKBP12 virtual screening pipeline
UFSRAT was used to select compounds similar to known inhibitors of FKBP12 from the
EDULISS database of small molecules. Three well characterised FKBP12 inhibitors were used
to generate UFSRAT queries. The results of running these queries with UFSRAT acted as the
starting point in a structure-based virtual screening pipeline (See Fig. 4).
Figure 4. The UFSRATworkflow.
doi:10.1371/journal.pone.0116570.g004
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Around 50% of atoms contained within the high affinity macrocyclic immunosuppressants
rapamycin and FK506 bind to FKBP12; the remainder exert a pharmacological effect by inter-
acting with a second protein; mTor and calcineurin respectively [29]. Both rapamycin and
FK506 share the same FKBP12 binding motif that occupies the majority of the active site mak-
ing four hydrogen bonds. A high resolution crystal structure of FKBP12 in complex with rapa-
mycin (2DG3.pdb), was used to select the buried fragment of rapamycin made up of atoms
within 3.5 Å of FKBP12 [30], defining the query molecule Q1 (See Fig. 4). Two additional que-
ries were selected from compounds from an NMR screen: 2-[(4-methylphenyl)sulfanyl]-1-
(morpholin-4-yl)ethan-1-one, Q2, and (2-[(4-methylbenzene)-sulfonyl]-1-(morpholin-4-yl)
ethan-1-one), Q3, (Fig. 4) [31]. The top 500 hits from UFSRAT were saved from each query
(1500 total, 0.04% of the database) and docked into template 2DG3.pdb using the program
LIDAEUS: grid spacing 0.6 Å; docking resolution parameter 0.04 Å [26, 32]. Ligands matching
the shape and atom types of the site-points were ranked according to scores describing the en-
thalpy and buriedness of the interaction and then filtered for drug-likeness using Lipinski’s cri-
teria and descriptors pre-calculated in the EDULISS data-base [33]. Manual inspection using
PyMol identified ligands with predicted poses occupying the base of the pocket and made at
least one hydrogen bond with Tyr82 or Ile56; hot spot residues in the active site of FKBP12.
Hits containing the same scaffold as the query were not selected for purchase.
The 11β-HSD1 virtual screening pipeline
Carbenoxolone, a potent bi-directional inhibitor of 11β-HSD1, was used to generate a UFSRAT
query [34] (see Fig. 5). The structure of carbenoxolone in complex with the enzyme is available
in the protein data bank with entry ID 2BEL. Candidate molecules were selected from the
EDULISS database, the FKBP12 workflow outlined in Fig. 4 was followed with the exception of
the docking step.
Testing virtual hits
All reagents were of the highest grade available. Compounds were purchased from: Chem-
bridge Corp., USA; InterBioScreen, Russia; Sigma Aldrich, UK; Specs, The Netherlands and
TimTec, USA. Recombinant human FKBP12 was expressed and purified as described in [35].
The purification of recombinant human 11β-HSD1 is described by Adie [36]. Visualization of
3D structures was performed using PyMOL [37] (open source, DeLano Scientific LLC).
Thermal denaturation fluorescence (TDF). A fluorescence based thermal denaturation
assay was used to detect binding to FKBP12 essentially as described in the study of Lo [38].
Final conditions were: 50 mM ammonium acetate, pH 7.0; 10 μM FKBP12; 250 μM
screening compound and 5x SYPRO orange dye (Invitrogen). The compound used for Q2,
2-[(4-methylphenyl)sulfanyl]-1-(morpholin-4-yl)ethan-1-one, acted as a positive control
(Kd = 15 μM, 27°C) [31]. Protein was melted over the temperature range 20 to 80°C; 0.5°C in-
crement, 30s hold. Compounds were screened for fluorescence in the absence of protein; all
samples were solvent matched and repeated in triplicate on 3 separate experiments. Apparent
equilibrium dissociation constants (Kd
app) for the interaction between the protein and ligands
were calculated from the change in mid-point melting temperature of the protein (Tm) on ad-
dition of ligand and transformed to 25°C using a benchmark value for the enthalpy of ligand
binding of -5 kcal∙mol-1 [39].
Electrospray ionization mass spectrometry. Electrospray-ionization mass spectrometry
(ESI-MS) was used to detect binding to FKBP12. Data was collected on a LCQTMDECA ion-
trap instrument (ThermoQuest) run in the positive ion mode. The analyte was introduced by
direct infusion and the following operating parameters were employed: nitrogen flow 100units,
UFSRAT Aided Discovery of FKBP12 and 11βHSD1 Inhibitors
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analyte flow 6 μl∙min-1, capillary voltage 3.5 kV, cone voltage 25 V and capillary temperature
50°C. Spectrum were averaged over 300 scans (2s/ scan) and processed using the Bioworks
Browser V 3.0 software package and ProMass 2.5 (ThermoScientific). The analyte solution
consisted of 100 μM ligand, 5 μM FKBP12 in 10% methanol (v/v), 10 mM ammonium acetate,
pH 6.8 incubated for 10 minutes at room temperature. Kd
app for the interaction between the
protein and ligand were calculated from the ratio of the intensity of the ion signal from free
protein and protein in complex with ligand using the method of Tjernberg [40].
Testing for inhibition of 11β-HSD1 reductase activity in cells. Candidate compounds
were tested for inhibition of the conversion of cortisone to cortisol by 11β-HSD1 expressed in
HEK-293 cells stably transfected with the full length human hsd11b1 gene as previously
Figure 5. Carbenoxolone, 20nM inhibitor of 11β-HSD1.
doi:10.1371/journal.pone.0116570.g005
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described [41]. An established scintillation proximity assay (SPA) was carried out in a 96-well
plate format, with appropriate controls [42]. Experiments were set up in triplicate with 8 inhib-
itor concentration points per compound, spanning 3.5 orders of magnitude. Final solution con-
ditions: 40 nM [3H]-cortisone; 50 mM Tris pH 8.0, 50 mMNaCl; 1% DMSO. The anti-cortisol
antibody was purchased from HyTest, Finland; radiometric quantification was carried out on a
Perkin Elmer TopCount instrument. The percentage inhibition was determined relative to a
non-inhibited control and the IC50 determined from a plot of percentage inhibition against
compound concentration. Data were fitted global nonlinear regression using Kaleidagraph
V4.0 (Synergy Software).
Testing for inhibition of 11β-HSD1 dehydrogenase activity. Candidate compounds were
tested for inhibition of the conversion of cortisol to cortisone by recombinant h11β-HSD1. The
dehydrogenation of cortisol is accompanied by the reduction of NADP+ to NADPH; this was
followed spectrophotometrically and scaled to a NADPH calibration curve. The excitation and
emission wavelengths were 340 and 458 nm. (SpectraMax M5, Molecular Devices). The experi-
mental conditions were 500 μMNADP, 1 μM 11β-HSD1, 200 μM cortisol 50 mM Tris, pH 7.7,
50 mMNaCl; 25°C. Reactions were carried out in sextuplicate. Ki
app were derived from a fit of
the rate of the reaction as a function of inhibitor concentration; Kaleidagraph, V4.0 [43]
Performance comparison of UFSRAT with USR using the DUD-E dataset. The Directory
of Useful Decoys: Extended (DUD-E) dataset [44] was used to compare the enrichment perfor-
mance of UFSRAT with USR. We also included the popular topological fingerprint ECFP4 [45]
as implemented in the RDKit toolkit [46]. Using 102 crystallographic ligands as query molecules
for targets within the DUD-E dataset, collections of molecules containing known actives for
each target along with random small molecules were run using each similarity method. Statistics
were then gathered on recall of known actives within the top scoring 0.5%, 1%, 2%, and 5% of
results. An enrichment score was then given to each method against each target. An enrichment
score of 1 denoting the number of hits found would be expected by random picking of com-
pounds. A score of 2 denoting double the expected recall over random picking and so on.
Results
Inhibitors of FKBP12
Of the 10 compounds tested, 4 compounds were hits in both the thermal denaturation fluores-
cence and ESI-MS screening assays. A compound was defined as a hit if it raised the mid-point
melting temperature of the protein by at least 0.5°C and in ESI-MS if hits were seen to fly as an
ion consistent with the mass of the protein-ligand complex. Structures of compounds 1 to 4 are
available in S3 Fig. and affinity data is shown in Table 1. ESI-MS spectra of FKBP12 ligand
complex are shown in Fig. 6.
Inhibitors of 11β-HSD1
Out of 26 compounds tested, 4 inhibited in cells and with recombinant human 11β-HSD1.
IC50 values for the SPA cell-based reductase assay and Ki
app for the fluorescent recombinant
protein dehydrogenase assay are shown in Table 2. Structures of compounds 5–8 are available
in S4 Fig. A compound was classified as a hit if it inhibited 11β-HSD1 by at least 40% in the
cell-based assay with a concentration of 100 μM inhibitor and 25% inhibition in the recombi-
nant protein assay. The fluorescence assay is less sensitive to inhibition due to the partial pres-
ence of carbenoxolone in the enzyme binding site as an artifact of the purification procedure.
This is reflected in lower inhibition by the same compounds in this assay, but may also be due
to differences in the ability of each compound to inhibit either the ‘reductase’ or ‘dehydroge-
nase’ forms of the enzyme.
UFSRAT Aided Discovery of FKBP12 and 11βHSD1 Inhibitors
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Performance comparison of UFSRAT with USR using the DUD-E
dataset
Comparing UFSRAT against USR in the recall of active molecules within the top 0.5%, 1%, 2%
and 5% of scores shows that UFSRAT consistently outperforms USR when enrichment is aver-
aged across the DUD-E targets. At the 0.5% level, average enrichments are 1.99 (USR) and 3.83
(UFSRAT), UFSRAT providing greater enrichment over USR for 75 out of 102 protein targets.
At the 1% level, average enrichments are 1.70 (USR) and 2.87 (UFSRAT), UFSRAT providing
greater enrichment over USR for 70 out of 102 protein targets. At the 2% level, average enrich-
ments are 1.41 (USR) and 2.27 (UFSRAT), UFSRAT providing greater enrichment over USR
for 67 out of 102 protein targets. Finally, at the 5% level, average enrichments are 1.09 (USR)
and 1.22 (UFSRAT), UFSRAT providing greater enrichment over USR for 68 out of 102 pro-
tein targets. For individual proteins in the DUD-E dataset, the largest difference in enrichment
when UFSRAT is outperformed is 5.6 for USR and 2.1 for UFSRAT, occurring at the 0.5%
level. The largest difference in enrichment when UFSRAT outperforms USR is 33.7 for
UFSRAT and 13.8 for USR at the 0.5% level. It is interesting to note that whilst UFSRAT
Table 1. Binding data for FKBP12.
Compound ID IUPAC name TDF* Kd
app (μM), Tm (transformed 25°C) ESI-MS* Kdapp (μM), 50°C
1 2-(phenacylcarbamoyl)benzoic acid 548±38 (252) 313±30
2 N-(2-hydroxy-1-methyl-2-phenyl-ethyl)benzamide 575±70 (266) 399±45
3 3-chloro-N-(2-hydroxy-2-phenyl-ethyl)benzamide 568±84 (263) 383±52
4 N-(2-acetamidophenyl)-3-phenyl-propanamide 648±88(303) 281±42
Q2 1-morpholino-2-(p-tolylsulfanyl)ethanone 28±8 (6)# 197±74
Molecules 1, 2 and 3 were retrieved using query molecules Q1, Q2 and Q3 and the UFSRAT technique, screened against the EDULISS database.
Binding of the top hits was tested using thermal denaturation (TDI) and mass spectrometry (ESI-MS).
* Recombinant human FKBP12
# Kd 15 μM, 27°C [31]
doi:10.1371/journal.pone.0116570.t001
Figure 6. Small molecules bound to FKBP12 in ESI-MS. P represents FKBP12 apoprotein and P:L protein
in complex with a ligand.
doi:10.1371/journal.pone.0116570.g006
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outperformed USR, both 3D techniques were greatly outperformed by ECFP4 in this test.
ECFP4 displaying on average, 8.9-fold enrichment at the 0.5% level, 11.9-fold at the 1% level,
7.7-fold at the 2% level, and 4-fold at the 5% level. However, whilst ECFP4 performs superbly
in this test, its performance can be accredited to the high degree of common substructures
shared by DUD-E actives, and absent amongst decoys. The nature by which ECFP and other
fingerprint methods operate are less amenable than 3D techniques to radical scaffold hopping
to the degree demonstrated by UFSRAT in the discovery 11β-HSD1 actives. Exhaustive results
for the recall of actives are available in the supporting data accompanying this report (see
S1 Fig. and S1–S6 Tables).
Discussion
The nature of UFSRAT as a ligand-based molecular similarity technique enables ligand discov-
ery whilst bypassing the need for any detailed structural information on the target. The 3D
conformation of a substrate or inhibitor indirectly encodes 3D and electrostatic properties of
the active form of the receptor. UFSRAT has an advantage over 1D and 2D-based molecular
similarity techniques, describing a complimentary shape to the binding pocket, something
which is not captured using 1D or 2D techniques. UFSRAT is also not prescriptive of bond
order, specific sub-structures or molecular orientation but does take into account the electro-
potential and therefore has the ability to discover bioisosteres, strengthening scaffold hopping
abilities as already demonstrated for 11β-HSD1.
Defining the similarity between two molecules in an objective way is a non-trivial problem.
Validating the success of a similarity program is difficult due to the absence of any absolute
metrics of similarity. However, performance comparison using the DUD-E dataset clearly
shows enhanced enrichment compared to the original USR method.
Comparison of query and candidate molecules by UFSRAT is sensitive to the conformation of
the molecules in question and one might therefore infer that the program would have most suc-
cess in biological assays if the receptor bound conformation of the query is known. In this study
UFSRAT has selected biologically active compounds from a query structure with known confor-
mation derived from a protein-ligand complex and a query where we have generated a low energy
conformer from a 2D representation. The pre-calculation of descriptors by UFSRATmeans that
it is possible to place descriptors for more than one low energy conformation in the database of
candidate compounds and also test multiple conformations of a query, thus reducing the chances
of missing a hit because virtual molecules were not in biologically relevant conformations.
In this study UFSRAT retrieved the highest affinity hits for 11β-HSD1. For this target the
correct biological conformation of the query carbenoxolone was available from
Table 2. Binding data for 11β-HSD1.
Compound ID IUPAC name SPA* IC50 (μM) Fluoresc.
# Ki
app (μM)
5 (1E,4E)-1,5-bis(3,4-dimethoxyphenyl)penta-1,4-dien-3-one 11.3±2.6 142 ± 66
6 Dihydroxyphenyl)-2-oxoethyl]sulfanyl}-1H-tetrazol-1-yl)benzamide 9.6±13.5 47 ± 13
7 1-(3,4-dihydroxyphenyl)-2-[(6-methoxy-1H-benzimidazol-2-yl)sulfanyl]ethanone 7.9±3.0 248 ± 73
8 1-(4-methoxyphenyl)-2-(2-pyridylsulfanyl)ethanone 0.067±0.003 26 ± 7
Molecules 5, 6, 7 and 8 were retrieved using carbenoxolone as a query molecule supplied to the UFSRAT technique and screened against the EDULISS
database. Binding of the top hits was tested using a scintillation proximity assay (SPA) and ﬂuorescence assay (Fluoresc).
* HEK-293 cells transfected with human 11β-HSD1
# Recombinant 11β-HSD1
doi:10.1371/journal.pone.0116570.t002
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crystallographic data. Interestingly, the top virtual hits were non-steroidal but did show simi-
larity to known 11β-HSD1 inhibitors demonstrating the ability of UFSRAT to scaffold hop.
By eye, carbenoxolone and all identified 11β-HSD1 active molecules are radically different
however, a key pattern of atoms involved in hydrogen bonding is preserved when examined in
3D (see S2 Fig.). Also, a survey of 11β-HSD1 non-steroidal inhibitors has shown that the ma-
jority share a central group or linker containing an atom that can act as a hydrogen bond ac-
ceptor, typically oxygen, flanked on either side by lipophilic groups [41]. This molecular
arrangement is observed with all the hit compounds in this study. Compound 6 contains a
linker with a 1,5-sulphanyl 1H-tetrazole moiety. A series of bioactive compounds containing
the same 1,5-sulphanyl 1H-tetrazole linker have been reported [41]. Compounds 6, 7 and 8 all
share the same linker between the lipophilic groups. The highest affinity hit is compound 8
which showed low nanomolar affinity IC50 in a cell based assay.
Compounds selected by UFSRAT that bind to FKBP12 with mid-micromolar affinity are
similar to the query compounds in that they share two ring systems joined by a linker contain-
ing a motif that has the potential to form hydrogen-bonding interactions with hot-spot resi-
dues in the active site. The affinity of the query compounds Q2 (15 μM) and Q3 (95 μM) (see
Fig. 4) for FKBP12 show that small changes to the linker have a significant affect on affinity.
Stebbins reports a series of analogues of Q1 (Fig. 4); substituting—S- with—S02-, -0- or—CH2-
all result in a reduction in affinity [31]. The biophysical techniques used to assess binding all
have the advantage of detecting low affinity ligands that have low solubility in solution.
However, as measurements are carried close to 50°C it is likely, in the majority of cases, that
the affinity would be higher at 25°C.
Conclusion
UFSRAT has been shown to be an efficient algorithm for selecting bioactive molecules from
large databases. Compounds have been identified that bind to two clinically relevant drug tar-
gets FKBP12 and 11β-HSD1. A key feature of the results is that the compounds selected by
UFSRAT do not have the same scaffold as query molecule, thus demonstrating the scaffold
hopping capabilities of USFRAT.
Supporting Information
S1 Fig. USR and UFSRAT enrichment rates for the recall of actives within the top n% of
scoring molecules using the DUDE dataset.
(TIF)
S2 Fig. Carbenoxolone (top) and 11β-HSD1 active compound #8 (lower) with key hydrogen
bond acceptor patter highlighted with approximate moments to center shown.
(TIF)
S3 Fig. 2D structures of compounds 1–4 and Q2.
(TIF)
S4 Fig. 2D structures of compounds 5–8.
(TIF)
S1 Table. Performance comparison statistics for enrichment in recall of active compounds
from the DUDE dataset.
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